Regeneron’s (REGN) Lymphoma Candidate Rejected by the FDA
ZacksRegeneron’s (REGN) efforts to expand its oncology portfolio get a hit as the FDA refuses to approve the lymphoma drug odronextamab.
Regeneron’s (REGN) efforts to expand its oncology portfolio get a hit as the FDA refuses to approve the lymphoma drug odronextamab.